# Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes

> **NCT04484363** · — · NO_LONGER_AVAILABLE · sponsor: **Takeda**

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Pevonedistat
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT04484363
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04484363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04484363, "Expanded Access Program With Pevonedistat (Given With Azacitidine) for Adults With Higher-risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04484363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*